Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1682 1693
This examiner grants 37% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17682759 | DETERMINING CELL TYPE ORIGIN OF CIRCULATING CELL-FREE DNA WITH MOLECULAR COUNTING | Non-Final OA | Guardant Health Inc. |
| 17776943 | STRUCTURE-BASED DESIGN OF THERAPEUTICS TARGETING RNA HAIRPIN LOOPS | Final Rejection | The Regents of the University of California |
| 17652172 | METHOD OF POOLING BLOOD SAMPLES | Final Rejection | Gen-Probe Incorporated |
| 18404829 | METHODS FOR ASSESSING RISK USING TOTAL AND SPECIFIC CELL-FREE DNA | Final Rejection | The Medical College of Wisconsin, Inc. |
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 16623725 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 16623719 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | Final Rejection | The Medical College of Wisconsin, Inc. |
| 17433542 | MULTIPLEXED SIGNAL AMPLIFICATION METHODS USING ENZYMATIC BASED CHEMICAL DEPOSITION | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17733762 | METHODS FOR DETECTING, MONITORING, AND GUIDING TREATMENT OF ALLOGRAFT REJECTION USING DISCRIMINATING GENE EXPRESSION SIGNATURES | Final Rejection | CareDx, Inc. |
| 17787499 | PRIMERS FOR DETECTING TRACE AMOUNT OF RARE SINGLE- NUCLEOTIDE VARIANT AND METHOD FOR SPECIFICALLY AND SENSITIVELY DETECTING TRACE AMOUNT OF RARE SINGLE-NUCLEOTIDE VARIANT BY USING SAME | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 17047006 | NON-INVASIVE DETECTION OF RESPONSE TO IMMUNOTHERAPY | Final Rejection | The Johns Hopkins University |
| 16809496 | METHOD OF IDENTIFYING RISK FOR AUTISM | Non-Final OA | The Johns Hopkins University |
| 19088496 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | Non-Final OA | Myriad Genetics, Inc. |
| 17353279 | METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY | Non-Final OA | Myriad Genetics, Inc. |
| 17905129 | METHODS OF USING A MULTI-ANALYTE APPROACH FOR DIAGNOSIS AND STAGING A DISEASE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 19012392 | METHODS OF IMPROVING SURVIVAL AND ELIMINATING TREATMENT-LIMITING TOXICITIES OF DICHLOROACETATE IN PATIENTS WITH PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18353647 | COMPOSITIONS AND METHODS FOR CHARACTERIZING ZDHHC1 DNA | Non-Final OA | Exact Sciences Corporation |
| 18038915 | METHOD FOR DETECTING SEVERITY OF ATOPIC DERMATITIS | Non-Final OA | KAO CORPORATION |
| 16764496 | METHODS TO MEASURE FUNCTIONAL HETEROGENEITY AMONG SINGLE CELLS | Final Rejection | The Regents of the University of Colorado, a body corporate |
| 18346973 | Quantum Dot-Nucleotide Based Ratiometric Fluorescent Molecular Beacon for Quantitative CRISPR/Cas Activity Detection | Non-Final OA | The Government of the United States of America, as represented by the Secretary of the Navy |
| 18254202 | SINGLE NUCLEOTIDE POLYMORPHISM MARKER FOR PREDICTING RISK OF ALZHEIMERS DISEASE AND USE THEREOF | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY |
| 17904348 | NUCLEIC ACID PROBES | Final Rejection | Agency for Science, Technology and Research |
| 18176152 | TESTING ASSAY FOR SCREENING AND DIAGNOSIS OF USHER, PENDRED, JERVELL, AND LANGE-NIELSEN SYNDROMES | Non-Final OA | Father Flanagan's Boys' Home Doing Business as Boys Town National Research Hospital |
| 18448868 | METHOD OF TREATMENT WITH TRADIPITANT | Final Rejection | Vanda Pharmaceuticals Inc. |
| 17005858 | B-CELL MATURATION COMPLEX CAR T CONSTRUCT AND PRIMERS | Non-Final OA | Janssen Biotech, Inc. |
| 17617183 | METHOD OF SIGNAL ENCODING OF ANALYTES IN A SAMPLE | Final Rejection | RESOLVE BIOSCIENCES GMBH |
| 17781646 | Multi-Biomarker Prediction Models for Multiple Infection Episodes Following Blunt Trauma | Non-Final OA | Shriners Hospitals for Children |
| 17999616 | A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE | Final Rejection | University of Ulster |
| 17193907 | PERSONALIZED MEDICINE APPROACH FOR TREATING COGNITIVE LOSS | Non-Final OA | University of North Texas Health Science Center at Fort Worth |
| 18254242 | METHOD FOR PREDICTING PATIENT RESPONSE TO CD40-TARGETED THERAPIES | Non-Final OA | Johannes Gutenberg University (JGU) Medical Center |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy